WO2024092106A3 - N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof - Google Patents

N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof Download PDF

Info

Publication number
WO2024092106A3
WO2024092106A3 PCT/US2023/077879 US2023077879W WO2024092106A3 WO 2024092106 A3 WO2024092106 A3 WO 2024092106A3 US 2023077879 W US2023077879 W US 2023077879W WO 2024092106 A3 WO2024092106 A3 WO 2024092106A3
Authority
WO
WIPO (PCT)
Prior art keywords
dmt
methods
dimethyltryptamine
making
compositions
Prior art date
Application number
PCT/US2023/077879
Other languages
French (fr)
Other versions
WO2024092106A2 (en
Inventor
Srinivas G Rao
Glen Short
Majed Fawaz
Prerak Patel
Santnu PATEL
Original Assignee
Atai Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/974,443 external-priority patent/US20230136824A1/en
Application filed by Atai Therapeutics, Inc. filed Critical Atai Therapeutics, Inc.
Publication of WO2024092106A2 publication Critical patent/WO2024092106A2/en
Publication of WO2024092106A3 publication Critical patent/WO2024092106A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pharmaceutical compositions including an amorphous N-N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt or prodrug thereof, and a polymeric carrier are described. These compositions are suitable for buccal or sublingual administration to a patient. Methods of treating disorders, including neurological disorders, by administration of these compositions are described.
PCT/US2023/077879 2022-10-26 2023-10-26 N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof WO2024092106A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/974,443 2022-10-26
US17/974,443 US20230136824A1 (en) 2021-04-26 2022-10-26 N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof

Publications (2)

Publication Number Publication Date
WO2024092106A2 WO2024092106A2 (en) 2024-05-02
WO2024092106A3 true WO2024092106A3 (en) 2024-06-06

Family

ID=90832092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/077879 WO2024092106A2 (en) 2022-10-26 2023-10-26 N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2024092106A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US20210346347A1 (en) * 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
WO2022061242A1 (en) * 2020-09-20 2022-03-24 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement
US20220267267A1 (en) * 2020-06-12 2022-08-25 Beckley Psytech Lmited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
US20220304980A1 (en) * 2019-07-04 2022-09-29 SW Holdings, Inc Metered dosing compositions and methods of use of psychedelic compounds
US20220339139A1 (en) * 2021-04-26 2022-10-27 ATAI Life Sciences AG Novel n,n-dimethyltryptamine compositions and methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220304980A1 (en) * 2019-07-04 2022-09-29 SW Holdings, Inc Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US20210346347A1 (en) * 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
US20220267267A1 (en) * 2020-06-12 2022-08-25 Beckley Psytech Lmited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
WO2022061242A1 (en) * 2020-09-20 2022-03-24 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement
US20220339139A1 (en) * 2021-04-26 2022-10-27 ATAI Life Sciences AG Novel n,n-dimethyltryptamine compositions and methods

Also Published As

Publication number Publication date
WO2024092106A2 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
TWI327573B (en) 6-11 bicyclic ketolide derivatives
MX2023008716A (en) Camptothecin compound, preparation method therefor, and application thereof.
CR20210627A (en) Benzisoxazole sulfonamide derivatives
CA2688708A1 (en) Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
CZ309247B6 (en) 40-O- (2-hydroxyethyl) rapamycin for use as the sole active ingredient in treating a solid tumour
HUP0203870A2 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
MXPA05010899A (en) Aminopyrimidine derivatives and their medical use.
TW200634021A (en) 3,6-bicyclolides
HK1081958A1 (en) Thienopyridazinone derivative as modulators of autoimmune diseases
US20110044917A1 (en) Dental composition for treating peri-implantitis
MX2022015419A (en) Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2).
AU2006226390B2 (en) Benzamidine derivatives for treatment and prevention of cancer therapy induced mucositis
NO20050018L (en) Lasofoxifene tablets and coatings
WO2005000863A3 (en) 6, 11-4c-bicyclic 9a-azalide derivatives
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
TN2020000161A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGIuR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
JP2016196493A (en) Use of l-butylphthalide in manufacturing of medicines for prevention and treatment of cerebral ischemia disease
WO2006039263A3 (en) NOVEL BICYCLIC 9a-AZALIDE DERIVATIVES
PH12019501968A1 (en) PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES
MX2021012223A (en) Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease.
WO2022115381A8 (en) Compositions and methods for treating cns disorders
WO2024092106A3 (en) N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
TW200635600A (en) Tetracyclic bicyclolides
MX2023011297A (en) Abhd6 antagonist.
MXPA01012936A (en) Pharmaceutical composition containing sibutramine and orlistat.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23883743

Country of ref document: EP

Kind code of ref document: A2